Clinical Trial Update: Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Roche is conducting a dose-escalation Phase 1/2 trial of a PD-1/LAG-3 bispecific antibody in patients with advanced or metastatic solid tumors. The study includ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• PD-1/LAG-3 bispecific antibody

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Solid Tumors, Metastatic Melanoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING